SUBSCRIBE
SUBSCRIBE

Mark Zipkin

Mark Zipkin (he/him) has been telling the stories of the biopharma space for over a decade. He is based in New Jersey with his wife, kids and a few-too-many cats. He can be reached at mark@markzipkin.com.

Female Project Manager running work on project timeline. Progress in business, Work process or work process, Timeline to success, Roadmap, Vector design illustration.
Obesity
Obesity Space Abuzz With Oral, Amylin Assets as Momentum Rides Into 2026
Biopharma’s obsession with the weight loss sector—projected to exceed $130 billion in revenue by 2035—shows no signs of slowing down as analysts gear up for a year that will test the oral market and provide key data on novel mechanisms.
February 6, 2026
 · 
4 min read
 · 
Mark Zipkin
Business
Codiak BioSciences Un-Strands Assets with Extracellular Vesicles
Codiak has two engineered exosome programs in Phase I, each showing different types of engineering possibilities to deliver targeted payloads that pharmaceutical companies haven’t managed to push all the way through the clinic.
August 16, 2021
 · 
6 min read
 · 
Mark Zipkin
Drug Development
Pandemic Highlights Opportunities, Challenges for Exosomes and Related Cell Therapies
New therapeutic modalities always face an uphill climb, but the urgency of COVID-19 may have opened the door for two related ones: cell therapies and exosomes.
August 10, 2021
 · 
7 min read
 · 
Mark Zipkin
BioMidwest
Tumors Next Target for T Cell Therapies with U Minnesota Research
New research shows T cells can be engineered to migrate more effectively inside tumor microenvironments, raising hopes of reproducing the remarkable outcomes seen for certain hematological cancer patient subsets in broader populations and indications.
June 17, 2021
 · 
4 min read
 · 
Mark Zipkin
Genetown
Seres Bolsters Rationale Behind GVHD, Cancer Programs at ASCO Meeting
With an oral presentation and a poster at the ASCO Annual Meeting this year, Seres Therapeutics sought to bolster the case for two of its microbiome therapeutics programs.
June 10, 2021
 · 
4 min read
 · 
Mark Zipkin
Companies Unlocking a New Class of Cancer Therapies with Sensitive METTL3 Tuning
University of Cambridge researchers published the first preclinical validation for a novel therapeutic strategy targeting epitranscriptomic modifiers of RNA, opening the door for spinout STORM Therapeutics’ AML therapy–and potentially much more.
May 25, 2021
 · 
5 min read
 · 
Mark Zipkin
Business
HAYA, RenBio Launch with Sights Set on Clinic
Two different companies, cardiac fibrosis RNA company HAYA Therapeutics and COVID-19 bispecific player RenBio, launched today with funding rounds designed to push them toward the clinic.
May 20, 2021
 · 
2 min read
 · 
Mark Zipkin
Drug Development
Ortho Dermatologics Announces More Positive Data for New Acne Vulgaris Therapy
On the back of the two positive Phase III trials, Ortho said it will submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2022.
April 22, 2021
 · 
2 min read
 · 
Mark Zipkin
Versant Raises $560 Million For New Early-Stage Biotech Fund
The fund will seek to invest in at least 20 startups located in the U.S., Canada, and Europe.
April 21, 2021
 · 
2 min read
 · 
Mark Zipkin
Biotech Beach
Medable Raises $194 Million In a Year to Push Digital Clinical Trials
Software company Medable raised a $78 million extension on its Series C round–totaling $194 million in venture funding over three raises in the past year–to tap the growing opportunity in decentralized digital clinical trials.
April 15, 2021
 · 
2 min read
 · 
Mark Zipkin
Business
Amarin CEO Thero to Retire as Company Pivots Focus to Global Markets
Amarin announced the forthcoming retirement of President and CEO John Thero, and the elevation of current head of commercial for Europe and senior vice president Karim Mikhail to the top role.
April 13, 2021
 · 
2 min read
 · 
Mark Zipkin
bakdc/Shutterstock
Drug Development
NIH to Back First Phase II Trials for COVID-19 Therapy Targeting Viral Proteases
The $3.1 million NCATS grant will help the company test SPI-1005 in two trials, both OK’d by the U.S. Food and Drug Administration (FDA) last August.
April 7, 2021
 · 
2 min read
 · 
Mark Zipkin
Business
Mineralys Launches With $40 Million for Hypertension Clinical Asset
Philadelphia-based Mineralys Therapeutics launched today with a $40 million Series A round to move its clinical asset, MLS-101, into Phase II testing for hypertension.
April 6, 2021
 · 
2 min read
 · 
Mark Zipkin
Deals
Rain Plans $100 Million IPO, Phase III Trial for Lead Precision Cancer Therapy
The news comes months after the company closed a $63 million Series B and inlicensed RAIN-32 from Daiichi Sankyo.
April 5, 2021
 · 
2 min read
 · 
Mark Zipkin
Drug Development
NKMax Rebrands As NKGen Ahead of Next Clinical Trial Launch, Off-The-Shelf Testing
Days after announcing the U.S. Food and Drug Administration (FDA) has cleared the next clinical trials to launch for its lead natural killer (NK) cell therapies, NKMax America announced it has renamed itself NKGen Biotech.
April 2, 2021
 · 
2 min read
 · 
Mark Zipkin
Load More